Nordic Health Summit 2016:
Antimicrobial Resistance – Are We Responding Too Late?
The third Nordic Health Summit focused on antimicrobial resistance.
The Nordic Health Summit aimed to create awareness, collaboration and a Nordic response to antimicrobial resistance. The perils antimicrobial resistance poses to usage of modern medicine and human welfare are quite severe. In order to counter this rapid development we invited the top Nordic healthcare managers and decision makers to come together.
During the Summit top international speakers shedded light over the current situation. One of the key speakers was: Keiji Fukuda, WHOs Special Representative for Antimicrobial Resistance.
Taking action through a Nordic Response
Failure to address antimicrobial resistance will affect everyone, regardless of their nationality or their country’s level of development. Indeed, by 2050, ten million people could be dying because of resistant bacteria. At that point, an estimated $100 trillion in global GDP will already have been lost.
As part of the Summit we presented a suggestion to a joint Nordic solution: a Nordic Response. Four key elements are critical to understand and manage the spread of drug-resistant strains:
Increase vital antimicrobial knowledge basis through Nordic research. In order to combat the resistance efficiently we need to comprehend the mechanisms that promote resistance.
Encourage development of new antibiotics both financially throught research funding and hospital prioritization.
Critical surveillance of patients carrying resistant bacteria and limiting interstate spreading. According to WHO, surveillance is the cornerstone for assessing the burden of AMR and for providing the necessary information for action in support of local, national and global strategies.
Global governance is essential for a solution. Antimicrobial resistance is a complex problem driven by many interconnected factors. Coordinated action is required to minimize emergence and spread of antimicrobial resistance.
The Summit was hosted in close collaboration with:
- John-Arne Røttingen, Director, Division of Infectious Disease Control, the Norwegian Institute of Public Health
- Ole Petter Ottersen, Rector, University of Oslo
- Arvid Hallén, Director General, The Research Council of Norway